Teicoplanin
Also known as: MDL 62873, Targocid, TEIC, Teichomycin A2, Teicoplanin, Teicoplanin A2
Source Teicoplanin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Teicoplanin is a semisynthetic glycopeptide used intravenously for serious infections caused by resistant Gram‑positive organisms, especially MRSA and enterococci.
Mechanism of Action
Binds to the D-Ala-D-Ala terminus of peptidoglycan precursors, inhibiting cell‑wall synthesis in Gram‑positive bacteria
Routes of Administration
Goals & Uses
- treatment of serious Gram‑positive infectionsAntibacterialHigh
- Treatment of skin and soft tissue infectionsAntimicrobial TherapyHigh
- Treatment of MRSA infectionsAntimicrobialHigh
- Treatment of Clostridioides difficile infectionAntimicrobialModerate
- Treatment of endocarditisAntimicrobial TherapyHigh
- Surgical prophylaxisInfection PreventionModerate
Contraindications
- Hypersensitivity to teicoplaninAllergyHigh
- Severe renal impairment (without dose adjustment)Organ ImpairmentModerate
- Known cross-reactivity with vancomycin in severe reactionsAllergyHigh
- pregnancy (first trimester)ReproductiveModerate
- hypersensitivity to teicoplanin or other glycopeptidesAllergyHigh
Adverse Effects
- rash / pruritusDermatologicCommon
- Injection site reactionsLocalCommon
- ThrombocytopeniaHematologicUncommonLow platelet count
- OtotoxicityAuditory/vestibularUncommon
- Infusion‑related reactionsGeneralCommon
- Red man syndromeInfusion ReactionUncommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- NephrotoxicityRenalCommon
Drug Interactions
- AminoglycosidesHigh
- CiclosporinModerate
- Aminoglycosides (e.g., gentamicin)Moderate
- NSAIDsModerateMay increase renal risk in susceptible patients
- Loop diuretics (e.g., furosemide)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Neonates and infantsPediatricRelative
- Renal impairmentOrgan ImpairmentRelative
- ElderlyAgeRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionApprovedApproved: complicated skin and soft‑tissue infections, bacteremia, endocarditis, osteomyelitisApproved for systemic treatment of Gram‑positive infections
- United StatesUnapprovedNot approved by FDA; may be obtained via IND for investigational use
- United KingdomApprovedApproved: serious Gram‑positive infections including MRSAAvailable under prescription in NHS formulary
Not FDA‑approved in the United States; approved in the EU and many other jurisdictions for systemic infections.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Teicoplanin?
Teicoplanin is a semisynthetic glycopeptide used intravenously for serious infections caused by resistant Gram‑positive organisms, especially MRSA and enterococci.
What is Teicoplanin used for?
Teicoplanin is educationally associated with: treatment of serious Gram‑positive infections, Treatment of skin and soft tissue infections, Treatment of MRSA infections, Treatment of Clostridioides difficile infection, Treatment of endocarditis, Surgical prophylaxis. Educational only — not medical advice.
How is Teicoplanin administered?
Recorded routes of administration: Intramuscular, Intravenous.
What are the potential side effects of Teicoplanin?
Reported adverse effects include: rash / pruritus, Injection site reactions, Thrombocytopenia, Ototoxicity, Infusion‑related reactions, Red man syndrome, Elevated liver enzymes, Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid Teicoplanin?
Recorded contraindications: Hypersensitivity to teicoplanin, Severe renal impairment (without dose adjustment), Known cross-reactivity with vancomycin in severe reactions, pregnancy (first trimester), hypersensitivity to teicoplanin or other glycopeptides. Consult a qualified clinician before use.